Correctly modeling the outcomes of new or existing oncological drugs is of importance for decision making at several levels. However, since data are quite often immature and several accompanying lines of therapy may have followed after initial treatment, a couple of challenges in approaching extrapolations or lines of therapy exist. In this session, presenters will give an overview of several frequently experienced issues and novel ways to approach these.